A Phase II Efficacy Trial of Pazopanib in Non-Clear Cell Metastatic Renal Cell Cancer (mRCC) PINCR
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2018
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 29 May 2018 Planned End Date changed from 16 May 2018 to 16 May 2019.
- 29 May 2018 Planned primary completion date changed from 16 May 2018 to 16 May 2019.
- 02 Feb 2018 Status changed from recruiting to active, no longer recruiting.